Autoimmune diseases are thought to arise from abnormalities in innate or adaptive immune responses and most likely have both genetic and environmental components. Diagnosis of autoimmune disease is often difficult, as the symptoms can be relatively nonspecific. Furthermore, no available blood test can accurately exclude the possibility of an autoimmune disease in a subject with such symptoms. At best, a battery of tests and a period of observation are usually required to establish that a patient does in fact have an autoimmune disorder. Using microarray technology, we have found that individuals with any of four distinct autoimmune diseases have a common gene expression signature that is independent of the specific clinical entity, but which is totally distinct from the normal immune response. Based upon these observations, we have developed a simple test for excluding the possibility that a subject has an autoimmune disorder. In Phase I we have shown that this test is present in early disease and has distinct differences from non-autoimmune disorders. We have confirmed the identities of the genes in our arrays and developed an approach for production of diagnostic arrays. This Phase II proposal is to continue this work has three specific aims. The first is to optimize the gene array platform. The second is to test the diagnostic tool in patients with early, undifferentiated disease and with other diseases to confirm specificity. The third is to compare the results to those obtained with existing tests. The result of this phase will be a test that is feasible for applications in research and clinical care

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
2R42AI053984-02
Application #
6838105
Study Section
Special Emphasis Panel (ZRG1-SSS-4 (10))
Program Officer
Prograis, Lawrence J
Project Start
2003-02-15
Project End
2006-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
2
Fiscal Year
2004
Total Cost
$361,393
Indirect Cost
Name
Arthrochip, LLC
Department
Type
DUNS #
148077766
City
Franklin
State
TN
Country
United States
Zip Code
37069
Spurlock 3rd, Charles F; Tossberg, John T; Guo, Yan et al. (2015) Defective structural RNA processing in relapsing-remitting multiple sclerosis. Genome Biol 16:58
Spurlock 3rd, Charles F; Tossberg, John T; Fuchs, Howard A et al. (2012) Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum 64:1780-9
Crooke, Philip S; Tossberg, John T; Horst, Sara N et al. (2012) Using gene expression data to identify certain gastro-intestinal diseases. J Clin Bioinforma 2:20
Tossberg, J T; Crooke, P S; Henderson, M A et al. (2012) Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis. Genes Immun 13:146-54
Spurlock 3rd, Charles F; Aune, Zachary T; Tossberg, John T et al. (2011) Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum 63:2606-16
Wang, Lily; Jia, Peilin; Wolfinger, Russell D et al. (2011) An efficient hierarchical generalized linear mixed model for pathway analysis of genome-wide association studies. Bioinformatics 27:686-92
Grayson, B L; Wang, L; Aune, T M (2011) Peripheral blood gene expression profiles in metabolic syndrome, coronary artery disease and type 2 diabetes. Genes Immun 12:341-51
Grayson, Britney L; Smith, Mary Ellen; Thomas, James W et al. (2010) Genome-wide analysis of copy number variation in type 1 diabetes. PLoS One 5:e15393
Liu, Zheng; Maas, Kevin; Aune, Thomas M (2006) Identification of gene expression signatures in autoimmune disease without the influence of familial resemblance. Hum Mol Genet 15:501-9